The Global First Generic

A New Wave of Scientific Discovery

No. 1 Oncology Company of Bangladesh

Beacon is the No. 1 oncology company of Bangladesh & manufactures latest anticancer drugs……..

Crizonix is the global first generic preparation of Crizotinib

Crizonix is indicated as the first-line treatment of adults with ALK-positive advanced Non-Small Cell Lung Cancer(NSCLC) and ROS-1 positive NSCLC. Crizotinib is an ALK and ROS-1 (c-ros oncogene 1 receptor tyrosine kinase) inhibitor.

Special features of Crizonix-

  • Manufactured in a dedicated oncology facility
  • Quality of Crizonix is to that of International Standard GMP compliant
  • Affordable to al patients at 13 times lesser price than originator
  • Worldwide delivery to your door step.

Click here to learn more

 About 2%-7% of people with NSCLC are considered to be ALK positive (ALK+) and approximately 1 % of the people with NSCLC  are ROS-1 positive.

BEACON Pharmaceuticals Limited launched US FDA approved Crizotinib at an affordable price for patients with NSCLC-

  • whose tumors are anaplastic lymphoma kinase (ALK) positive (see clinical studies) &
  • whose tumors are ROS-1 positive

It is in capsule form & has to take twice daily.

Crizotinib is the only US FDA approved treatment for patients with ALK positive & ROS-1 positive NSCLC. It is not yet known whether Crizonix is safe and effective in children.

Serving Breakthrough


Know About Lung


Latest News

& Media

Beacon Introduces Global Patient Support Program

Life saving drugs are either beyond the reach of general

people or not available in many countries. Because of

the patient exemptions for Bangladeshi companies,

Beacon Pharmaceuticals can manufacture the patented

drugs. As a support to global patient… Read more

Registered & Licensed by Regulatory
Authority of Bangladesh

Crizonix is a registered product by the Directorate General

of Drug Administration & Licensing Authority (Drugs) of

Bangladesh. Drug Registration Number: 341-293-10

Inclusion Date: 20-07-2016 Valid up to: 19-07-2021

“Lung cancer is difficult to treat, in part, because patients have different mutations, some of which are rare,”

Richard Pazdur, M.D., Director of the Office of Hematology and Oncology Products, FDA